For the three months ended December 31, 2022 and 2021, we recorded net gains of $31 million and charges of $26 million, respectively, and for the nine months ended December 31, 2022 and 2021, we recorded net gains of $66 million and charges of $517 million, respectively, in total operating expenses to remeasure the assets and liabilities of our E. U. disposal group to fair value less costs to sell.For the nine months ended December 31, 2022, the contribution was approximately $639 million and $186 million to segment revenues and segment operating profit, respectively, and for the nine months ended December 31, 2021, the contribution was approximately $1.4 billion to segment revenues and, including total inventory charges that are further described below, increased our segment operating profit by approximately $121 million.The Settlement only addresses the claims of attorneys general of U. S. states and territories and political subdivisions in participating states and territories.A last-in, first-out (“ LIFO”) inventory charge of $5 million and a credit of $33 million were recognized during the three months ended December 31, 2022 and 2021, and credits of $31 million and $79 million were recognized during the nine months ended December 31, 2022 and 2021, respectively.Restructuring Initiatives and Long-Lived Asset ImpairmentsWe recorded restructuring, impairment, and related charges of $31 million and $18 million for the three months ended December 31, 2022 and 2021, respectively, and $84 million and $208 million for the nine months ended December 31, 2022 and 2021, respectively.We recorded charges of $5 million and $115 million for the three and nine months ended December 31, 2021, respectively, primarily related to lease right-of-use and other long-lived asset impairments, lease exit costs, and accelerated depreciation and amortization.Income Tax ExpenseFor the three months ended December 31, 2022 and 2021, we recorded income tax expense of $329 million and $238 million, respectively.For the nine months ended December 31, 2022 and 2021, we recorded income tax expense of $799 million and $396 million, respectively.Our reported income tax rates were 22.7% and 85.9% for the three months ended December 31, 2022 and 2021, respectively, and 21.6% and 30.9% for the nine months ended December 31, 2022 and 2021, respectively.Net Income (Loss) Attributable to McKesson CorporationNet income (loss) attributable to McKesson Corporation was $1.1 billion and $(7) million for the three months ended December 31, 2022 and 2021, respectively, and $2.8 billion and $746 million for the nine months ended December 31, 2022 and 2021, respectively.Diluted earnings (loss) per common share attributable to McKesson Corporation was $7.66 and $(0.04) for the three months ended December 31, 2022 and 2021, respectively, and $19.30 and $4.79 for the nine months ended December 31, 2022 and 2021, respectively.53 McKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED) Weighted-Average Diluted Common Shares OutstandingDiluted earnings per common share were calculated based on a weighted-average number of shares outstanding of 141.0 million and 151.6 million for the three months ended December 31, 2022 and 2021, respectively, and 143.7 million and 155.8 million for the nine months ended December 31, 2022 and 2021, respectively.Within the segment, sales to primary care and extended care customers decreased $30 million and $5 million, respectively.The decrease in our primary care business was driven by lower sales of COVID-19 tests, partially offset by underlying core business growth.Within the segment, sales to primary care and extended care customers decreased $170 million and $3 million, respectively.The decrease in our primary care business was driven by lower sales of COVID-19 tests, partially offset by underlying core business growth including higher sales of flu test kits.Within the segment, foreign currency exchange fluctuations were unfavorable by $461 million and sales in Europe declined by $4.9 billion, partially offset by increased sales in Canada of $318 million.Within the segment, foreign currency exchange fluctuations were unfavorable by $1.7 billion and sales in Europe declined by $9.6 billion, partially offset by increased sales in Canada of $718 million.(4) Operating profit for our International segment includes the following: • charges of $3 million and $240 million for the three and nine months ended December 31, 2022, respectively, and charges of $58 million and $400 million for the three and nine months ended December 31, 2021, respectively, to remeasure the assets and liabilities of our E. U. disposal group to fair value less costs to sell and, in fiscal 2022, to impair certain assets, including internal-use software that will not be utilized in the future; • charges of $787 million for the three and nine months ended December 31, 2021 to remeasure the assets and liabilities of our U. K. disposal group to fair value less costs to sell; and • a gain of $59 million for the nine months ended December 31, 2021 related to the sale of our Canadian health benefit claims management and plan administrative services business.Operating ActivitiesOperating activities provided cash of $1.8 billion and $1.5 billion during the nine months ended December 31, 2022 and 2021, respectively.Operating activities for the nine months ended December 31, 2022 were affected by net income of $2.9 billion, increases in drafts and accounts payable of $3.5 billion, receivables of $2.2 billion, and inventories of $2.2 billion, all primarily driven by higher revenues and timing.Investing activities for the nine months ended December 31, 2022 and 2021 includes $376 million and $380 million, respectively, in capital expenditures for property, plant, and equipment, and capitalized software, and reflects proceeds from sales of businesses and investments of $1.1 billion, including cash proceeds, net of cash divested, of $573 million from the completed divestiture of our E. U. disposal group, $202 million of net cash from the completed divestiture of our U. K. disposal group, and $179 million of cash from the exit of one our investments in equity securities in July 2022.Financing ActivitiesFinancing activities used cash of $3.2 billion and $4.3 billion during the nine months ended December 31, 2022 and 2021, respectively, which includes $3.5 billion and $2.0 billion of cash paid for share repurchases, respectively, as well as $216 million and $206 million of cash paid for dividends, respectively.Financing activities also includes cash receipts of $1.1 billion and $3.6 billion for the nine months ended December 31, 2022 and 2021, respectively, and repayments of $483 million and $3.3 billion for the nine months ended December 31, 2022 and 2021, respectively, for short-term borrowings, primarily commercial paper.Our cash and cash equivalents balance as of December 31, 2022 and March 31, 2022 included approximately $849 million and $1.5 billion of cash held by our subsidiaries outside of the U. S., respectively.